Japanese Takeda Buys Abbott’s Stake In TAP Joint U.S. Venture
This article was originally published in PharmAsia News
Executive Summary
Japanese drug maker Takeda will establish Takeda America Holdings after finalizing a deal March 19 to obtain a 100 percent stake in TAP Pharmaceutical Products, its 50/50 joint venture with Abbott
You may also be interested in...
Takeda/Millennium’s Phase III IBD Drug Promises Improved Safety
Millennium Pharmaceuticals, which in this case could call itself "The Takeda Gastroenterology Company," announced Jan. 22 that it has launched Phase III trials of its anti-inflammatory biologic MLN0002 in two kinds of inflammatory bowel disease
Takeda/Millennium’s Phase III IBD Drug Promises Improved Safety
Millennium Pharmaceuticals, which in this case could call itself "The Takeda Gastroenterology Company," announced Jan. 22 that it has launched Phase III trials of its anti-inflammatory biologic MLN0002 in two kinds of inflammatory bowel disease
Takeda’s Febuxostat Gets U.S. FDA Advisory Committee Nod for Gout; Cardio Risk Remains A Concern
A U.S. FDA advisory committee voted in favor of approving Takeda's gout therapy febuxostat during a Nov. 24 meeting, but strongly encouraged the agency to use its post-approval authorities to further explore a potential cardiovascular signal detected in clinical trials